Literature DB >> 24933113

Myc and its interactors take shape.

William B Tu1, Sara Helander2, Robert Pilstål2, K Ashley Hickman1, Corey Lourenco1, Igor Jurisica1, Brian Raught1, Björn Wallner2, Maria Sunnerhagen2, Linda Z Penn3.   

Abstract

The Myc oncoprotein is a key contributor to the development of many human cancers. As such, understanding its molecular activities and biological functions has been a field of active research since its discovery more than three decades ago. Genome-wide studies have revealed Myc to be a global regulator of gene expression. The identification of its DNA-binding partner protein, Max, launched an area of extensive research into both the protein-protein interactions and protein structure of Myc. In this review, we highlight key insights with respect to Myc interactors and protein structure that contribute to the understanding of Myc's roles in transcriptional regulation and cancer. Structural analyses of Myc show many critical regions with transient structures that mediate protein interactions and biological functions. Interactors, such as Max, TRRAP, and PTEF-b, provide mechanistic insight into Myc's transcriptional activities, while others, such as ubiquitin ligases, regulate the Myc protein itself. It is appreciated that Myc possesses a large interactome, yet the functional relevance of many interactors remains unknown. Here, we discuss future research trends that embrace advances in genome-wide and proteome-wide approaches to systematically elucidate mechanisms of Myc action. This article is part of a Special Issue entitled: Myc proteins in cell biology and pathology.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Myc; Post-translational modification; Protein structure; Protein–protein interaction; Transcriptional regulation

Mesh:

Substances:

Year:  2014        PMID: 24933113     DOI: 10.1016/j.bbagrm.2014.06.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  48 in total

Review 1.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

2.  Deubiquitinating c-Myc: USP36 steps up in the nucleolus.

Authors:  Xiao-Xin Sun; Rosalie C Sears; Mu-Shui Dai
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay.

Authors:  Xiulei Mo; Qi Qi; Andrei A Ivanov; Qiankun Niu; Yin Luo; Jonathan Havel; Russell Goetze; Sydney Bell; Carlos S Moreno; Lee A D Cooper; Margaret A Johns; Fadlo R Khuri; Yuhong Du; Haian Fu
Journal:  Mol Pharmacol       Date:  2017-01-13       Impact factor: 4.436

4.  Biophysical and Structural Methods to Study the bHLHZip Region of Human c-MYC.

Authors:  Giovanna Zinzalla
Journal:  Methods Mol Biol       Date:  2021

Review 5.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

6.  A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.

Authors:  Huabo Wang; Anand Ramakrishnan; Steven Fletcher; Edward V Prochownik
Journal:  J Biol Methods       Date:  2015

7.  Pre-Anchoring of Pin1 to Unphosphorylated c-Myc in a Fuzzy Complex Regulates c-Myc Activity.

Authors:  Sara Helander; Meri Montecchio; Robert Pilstål; Yulong Su; Jacob Kuruvilla; Malin Elvén; Javed M E Ziauddin; Madhanagopal Anandapadamanaban; Susana Cristobal; Patrik Lundström; Rosalie C Sears; Björn Wallner; Maria Sunnerhagen
Journal:  Structure       Date:  2015-11-19       Impact factor: 5.006

Review 8.  MYC protein interactors in gene transcription and cancer.

Authors:  Diana Resetca; Cornelia Redel; Corey Lourenco; Peter Lin; Alannah S MacDonald; Roberto Ciaccio; Tristan M G Kenney; Yong Wei; David W Andrews; Maria Sunnerhagen; Cheryl H Arrowsmith; Brian Raught; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2021-06-29       Impact factor: 60.716

9.  PELI1 expression is correlated with MYC and BCL6 expression and associated with poor prognosis in diffuse large B-cell lymphoma.

Authors:  Ji-Young Choe; Mira Park; Ji Yun Yun; Hee Young Na; Heounjeong Go; Hyun-Jung Kim; Sohee Oh; Ji Eun Kim
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

10.  Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.

Authors:  Hai Vu Nguyen; Cassandra J Vandenberg; Ashley P Ng; Mikara R Robati; Natasha S Anstee; Joel Rimes; Edwin D Hawkins; Suzanne Cory
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.